

Anthony C Keech

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6906063/publications.pdf>

Version: 2024-02-01

97
papers

11,023
citations

81743
39
h-index

42291
92
g-index

97
all docs

97
docs citations

97
times ranked

10668
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>Guidelineâ€based</scp> audit of the hospital management of heart failure with reduced ejection fraction. Internal Medicine Journal, 2023, 53, 1595-1601.	0.5	1
2	Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care, 2022, 45, 701-709.	4.3	37
3	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011382.	1.4	10
4	Relative leukocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia, 2022, 65, 375-386.	2.9	11
5	Subclinical valve thrombosis in transcatheter aortic valve implantation: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1491-1499.e2.	0.4	20
6	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139.	3.0	50
7	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology, 2021, 77, 259-267.	1.2	24
8	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	2.4	7
9	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	1.6	6
10	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.4	37
11	Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes-analysis from the Hong Kong Diabetes Register. Diabetes Research and Clinical Practice, 2021, 173, 108649.	1.1	10
12	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2021, 42, 2765-2775.	1.0	119
13	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsâ€• A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial â€•. Circulation Journal, 2021, 85, 2063-2070.	0.7	13
14	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 2021, 144, 249-251.	1.6	7
15	Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study. Heart Lung and Circulation, 2021, 30, 1918-1928.	0.2	6
16	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation, 2021, 144, 1732-1734.	1.6	14
17	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	1.6	1
18	Protocol for the Stimulating Î² ₃ -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease. BMJ Open, 2021, 11, e049858.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	1.1	3
20	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. European Heart Journal, 2021, 42, 4821-4829.	1.0	23
21	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.	3.3	54
22	Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves. JACC: Cardiovascular Interventions, 2021, 14, 2503-2515.	1.1	10
23	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 2021, 11, e044656.	0.8	0
24	Prevalence of diabetic retinopathy and reduced vision among Indigenous Australians in the nurse-led IDEES study in a regional primary care clinic. Internal Medicine Journal, 2021, , .	0.5	0
25	Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)â€”Rationale and Design. Frontiers in Pediatrics, 2021, 9, 799125.	0.9	19
26	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 2021, 11, e044656.	0.8	8
27	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. Circulation, 2020, 141, 616-623.	1.6	143
28	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327â€”037 participants. Lancet Diabetes and Endocrinology, 2020, 8, 36-49.	5.5	115
29	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	4.3	85
30	Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice, 2020, 169, 108450.	1.1	6
31	Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register. Diabetes Care, 2020, 43, 2257-2265.	4.3	31
32	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3638-e3649.	1.8	37
33	Questioning statin therapy for older patients â€” Authors' reply. Lancet, The, 2020, 395, 1832-1833.	6.3	0
34	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	6.3	167
35	A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 444-455.	1.0	17
36	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. JAMA Cardiology, 2020, 5, 787.	3.0	23

#	ARTICLE	IF	CITATIONS
37	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	1.2	62
38	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 2020, 141, 1600-1607.	1.6	61
39	Rare case of infiltrative cardiomyopathy secondary to scleromyxedema. Internal Medicine Journal, 2020, 50, 127-128.	0.5	2
40	Uric acid predicts cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes, Obesity and Metabolism, 2020, 22, 1388-1396.	2.2	6
41	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke, 2020, 51, 1546-1554.	1.0	102
42	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	3.0	56
43	Suggested clinical approach for the diagnosis and management of "statin intolerance" with an emphasis on muscle-related side effects. Internal Medicine Journal, 2019, 49, 1081-1091.	0.5	15
44	Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate. Journal of Cell Communication and Signaling, 2019, 13, 523-530.	1.8	11
45	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Journal of the American College of Cardiology, 2019, 73, 2961-2970.	1.2	115
46	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. JAMA Cardiology, 2019, 4, 613.	3.0	66
47	The case for extended thromboprophylaxis in medically hospitalised patients "not yet made. European Journal of Preventive Cardiology, 2019, , 204748731983657.	0.8	2
48	Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPAR-Independent Modulation of Thioredoxin-Interacting Protein. Diabetes, 2019, 68, 1040-1053.	0.3	22
49	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism: Clinical and Experimental, 2019, 93, 93-99.	1.5	24
50	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab. JAMA Cardiology, 2019, 4, 59.	3.0	45
51	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
52	Attractions and barriers to Australian physician-researcher careers. Internal Medicine Journal, 2019, 49, 171-181.	0.5	12
53	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. Diabetes Care, 2018, 41, 1244-1250.	4.3	16
54	Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes and Endocrinology, the, 2018, 6, 310-318.	5.5	43

#	ARTICLE	IF	CITATIONS
55	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 756-766.	1.6	200
56	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. <i>Circulation</i> , 2018, 138, 712-723.	1.6	93
57	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€“Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	1.2	15
58	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018, 138, 131-140.	1.6	194
59	Clinical benefits of evolocumab appear less than hoped â€“ Authors' reply. <i>Lancet</i> , The, 2018, 391, 934-935.	6.3	2
60	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
61	Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 156-167.	1.1	4
62	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. <i>JAMA Cardiology</i> , 2018, 3, 749.	3.0	105
63	Design and rationale of the <sc>EBBINGHAUS</sc> trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapyâ€“A cognitive study of patients enrolled in the <sc>FOURIER</sc> trial. <i>Clinical Cardiology</i> , 2017, 40, 59-65.	0.7	54
64	Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. <i>Heart Rhythm</i> , 2017, 14, 866-874.	0.3	47
65	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
66	Delayed versus Immediate Cord Clamping in Preterm Infants. <i>New England Journal of Medicine</i> , 2017, 377, 2445-2455.	13.9	228
67	Triglyceride-lowering trials. <i>Current Opinion in Lipidology</i> , 2017, 28, 477-487.	1.2	12
68	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1069.	3.0	119
69	Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). <i>Contemporary Clinical Trials</i> , 2017, 62, 37-42.	0.8	8
70	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 941-950.	5.5	452
71	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643.	13.9	366
72	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385.	3.0	89

#	ARTICLE	IF	CITATIONS
73	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet</i> , The, 2017, 390, 1962-1971.	6.3	487
74	HDL as a Target for Glycemic Control. <i>Current Drug Targets</i> , 2017, 18, 651-673.	1.0	4
75	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease. <i>Circulation</i> , 2016, 133, 1851-1860.	1.6	48
76	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>American Heart Journal</i> , 2016, 173, 94-101.	1.2	158
77	Nonsyndromic Thoracic Aortic Aneurysm and Dissection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 618-626.	1.2	46
78	Opposite associations between alanine aminotransferase and $\hat{\Gamma}^3$ -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 783-793.	1.5	20
79	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Atherosclerosis</i> , 2015, 242, 295-302.	0.4	19
80	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
81	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	0.8	42
82	Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 521-528.	4.3	127
83	Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 328-336.	1.1	12
84	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2351-2358.	4.3	50
85	Peroxisome Proliferator-Activated Receptor $\hat{\Gamma}^{\pm}$ Protects Capillary Pericytes in the Retina. <i>American Journal of Pathology</i> , 2014, 184, 2709-2720.	1.9	71
86	The Relationship between Endothelial Progenitor Cell Populations and Epicardial and Microvascular Coronary Disease—A Cellular, Angiographic and Physiologic Study. <i>PLoS ONE</i> , 2014, 9, e93980.	1.1	12
87	Therapeutic Effects of PPAR $\hat{\Gamma}^{\pm}$ Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. <i>Diabetes</i> , 2013, 62, 261-272.	0.3	148
88	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012, 163, 508-514.	1.2	24
89	The role of statin therapy in patients with lower vascular risk. <i>Medical Journal of Australia</i> , 2012, 197, 130-131.	0.8	0
90	Cost-effectiveness Considerations of Cardiovascular Therapeutics. <i>Heart Lung and Circulation</i> , 2009, 18, 118-122.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1780-1788.	6.3	270
92	Interpreting the results of a clinical trial. <i>Medical Journal of Australia</i> , 2007, 186, 318-319.	0.8	6
93	Putting results of a clinical trial into perspective. <i>Medical Journal of Australia</i> , 2007, 186, 368-370.	0.8	2
94	Balancing the outcomes: reporting adverse events. <i>Medical Journal of Australia</i> , 2004, 181, 215-218.	0.8	23
95	Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose: Results from the LIPID trial. <i>Diabetes Care</i> , 2003, 26, 2713-2721.	4.3	295
96	Selecting participants for clinical trials. <i>Medical Journal of Australia</i> , 2001, 175, 490-491.	0.8	1
97	Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. <i>Clinical Endocrinology</i> , 1996, 45, 435-441.	1.2	116